Artículos de revistas
Albumin nanocarriers, γ- irradiated crosslinked, combined with therapeutic drugs for cancer therapy
Fecha
2017-10Registro en:
Siri, Macarena; Achilli, Estefanía Edith; Grasselli, Mariano; Alonso, Silvia del Valle; Albumin nanocarriers, γ- irradiated crosslinked, combined with therapeutic drugs for cancer therapy; Bentham Science Publishers; Current Pharmaceutical Design; 23; 35; 10-2017; 5272-5282
1381-6128
CONICET Digital
CONICET
Autor
Siri, Macarena
Achilli, Estefanía Edith
Grasselli, Mariano
Alonso, Silvia del Valle
Resumen
Albumin polymeric Nanoparticles (NPs) have opened a great expectancy as for controlled drug delivery due to their therapeutic potency. Concomitantly biodegradable NPs technologies with target linked structures to pave the way of personalised medicine are becoming increasingly important in sight of a therapeutically effective research technology. This is particularly attractive for nanoparticle-based cancer delivery systems, based on the known limitations and efforts to overcome. This new group of gamma irradiated-NPs inherited both the protein delivery properties and robustness of polymer forming structures, and gamma irradiation techniques that leave clean, innocuous and biodegradable NPs. These protein NPs made of serum albumin are referred to SA NPs that possesses several characteristics making them especially attractive to be considered as a drug delivery system. This review focused on methodologies actually being used in the synthesis and characterisation of albumin NPs and different author’s opinions on strategic ways to treat cancerous cell-lines with NPs. Utterly, challenges being overthrown by researchers are brought up to anneal an effective, all in one targeted albumin NPs to passed through in vitro and preclinical trials.